Investigators conducted a retrospective study to better understand whether there is an equally shared risk for C difficile infection across immunosuppressant classes.
A multidisciplinary panel comprising members from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America created guidelines for health care professionals caring for patients with C difficile infection.
Investigators evaluated the safety and effectiveness of bezlotoxumab to prevent recurrent C difficile infection in patients having undergone solid organ or hematopoietic cell transplantation.
A team of investigators evaluated outcomes following probiotic use for primary prevention of Clostridioides difficile infection in hospitalized patients.
Publication of the revised clinical practice guidelines for Clostridioides difficile infection was followed by significant increases in use of oral vancomycin and fidaxomicin, and a significant decrease in use of oral metronidazole.
“These positive preliminary findings represent a major step forward towards bringing an innovative, non-antibiotic option to patients that may help restore their gut microbiome,” said Per Falk, Ferring’s President and Chief Science Officer.
As a result of a decline in healthcare–associated infections, the estimated burden of Clostridioides difficile infection in the United States decreased by an adjusted 24% from 2011 through 2017.
Features of fecal microbiota at baseline and after antibiotic therapy may be predictive of recurrent Clostridiodes difficile infection in patients with and without ulcerative colitis.
The FDA has approved fidaxomicin for the treatment of Clostridioides difficile-associated diarrhea in adult and pediatric patients aged 6 months and older.
Dual therapy with intravenous metronidazole and oral vancomycin is not superior to oral vancomycin alone in the treatment of Clostridioides difficile infections.